Seeking Alpha

La Jolla Pharma +22.8% AH on positive trial results

  • La Jolla's (LJPC) Phase 2 trial of its GCS-100 chronic kidney disease drug "met its primary efficacy endpoint of a statistically significant improvement in kidney function." A 1.5 mg/m2 dose led to a statistically significant increase in estimated glomerular filtration rate relative to a a placebo. (PR)
  • Secondary endpoints were also achieved, and 117 out of 121 enrolled patients completed treatment.
  • La Jolla: "We hope to use these results as a platform for further investigation not only in chronic kidney disease but also in other diseases where tissue fibrosis plays a central role."
  • CC tomorrow at 8:30AM ET. Ahead of the CC, management is presenting at a Roth conference at 5:30PM ET today (webcast).
  • Wedbush launched coverage with an Outperform last month, arguing there was a "70% probability of a positive outcome" for the trial.
Comments (1)
  • panchosfc
    , contributor
    Comments (36) | Send Message
     
    What is the potential for the platform? And for which other diseases with tissue fibrosis can be used?
    10 Mar, 05:13 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|